Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial (07 May 2008) First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra in adolescents 11-18 years of age compared to Menactra®. Infection with any... compared to Menactra, show that adolescents who were immunized with Menveo generated...% with Menactra, as measured by the hSBA assay. Serogroup Y causes approximately 39...
Top